Khon Kaen University
kku.ac.thTotal trials
159
Active
8
Phase 3
20
Total enrollment
25,241
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Morphine Sulfate | — | — | — | — | — | 1 | |
| 10% urea lotion plus 1% cannabidiol | — | — | — | — | — | 1 | |
| Control | — | — | — | — | — | 1 | |
| Triamcinolone (TAC) 0.1% cream | — | — | — | — | — | 1 | |
| Triamcinolone Acetonide 0.1% Oromucosal Paste | — | — | — | — | — | 1 |
Next readouts
- 2025-05
- 2025-10-31
- 2026-05-01
- 2027-12
Top conditions
- Healthy5
- Spinal Cord Injuries5
- Postoperative Nausea and Vomiting4
- Postoperative Complications3
- Retinal Vascular3
- Anesthesia3
- Systemic Sclerosis3
- Injuries, Spinal Cord3
Frequently asked questions about Khon Kaen University
- How many clinical trials does Khon Kaen University have on ClinicalTrials.gov?
- Khon Kaen University is listed as the lead sponsor on 159 clinical trials in ClinicalTrials.gov, 8 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Khon Kaen University's trials are in Phase 3?
- 20 of Khon Kaen University's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does Khon Kaen University focus on?
- Khon Kaen University's most-studied conditions on ClinicalTrials.gov are Healthy, Spinal Cord Injuries, Postoperative Nausea and Vomiting, Postoperative Complications, Retinal Vascular.
- When are Khon Kaen University's next clinical trial readouts?
- Khon Kaen University has 4 upcoming primary-completion readouts tracked here; the soonest is “Mucoadhesive Film With/without Acmella Oleracea & Triamcinolone Acetonide for Aphthous Ulcers”, expected around 2025-05.